Hormone replacement therapy does not appear to increase the risk of common, benign ovarian cysts in postmenopausal women. One study found that cyst prevalence was actually lower among early postmenopausal HRT users compared to non-users. But “ovarian cysts” is a broad category, and the answer shifts depending on the type of cyst involved. Endometriosis-related cysts, for instance, can be reactivated by certain HRT regimens, and the formulation of HRT matters enormously for long-term ovarian health.
What the Evidence Says About Common Functional Cysts
The most common type of ovarian cyst in premenopausal women is a functional cyst, which forms as a normal byproduct of ovulation. After menopause, ovulation stops, so functional cysts become much less common on their own. The worry is whether HRT might restart enough ovarian activity to produce new cysts or enlarge existing ones.
A study of postmenopausal women using cyclic HRT found no overall difference in the prevalence of ovarian cysts between HRT users and non-users, with rates of about 10.5% and 12.5% respectively. Among early postmenopausal women aged 40 to 55, HRT users actually had a significantly lower prevalence of ovarian cysts compared to non-users, roughly 10% versus nearly 29%.1PubMed. Ovarian cysts and cyclic hormone replacement therapy: is there an association? That finding may seem counterintuitive, but it aligns with how HRT interacts with the ovary during the transition into menopause. In early postmenopause, ovaries can still produce erratic bursts of hormonal activity. HRT appears to smooth out some of that irregular signaling, which could reduce the likelihood of cyst formation rather than increase it.
This does not mean HRT actively shrinks cysts that are already present. It means that for the garden-variety functional cyst, starting HRT is unlikely to make things worse and may reduce the chance of new ones forming in the years right after menopause.
How HRT Alters Ovarian Signaling
The ovaries do not operate in isolation. They are part of a feedback loop with the pituitary gland in the brain. When estrogen levels drop at menopause, the pituitary ramps up its output of follicle-stimulating hormone and luteinizing hormone, essentially shouting at the ovaries to keep working. That elevated signaling can sometimes push residual ovarian tissue into forming small cysts.
Research on recently menopausal women has shown that different HRT formulations change this feedback loop in different ways. Two common regimens, when compared directly, produced distinct patterns of pituitary and ovarian hormone levels, altering the way the brain and the ovaries communicate.2PubMed Central. Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback The practical takeaway is that not all HRT is the same when it comes to ovarian effects. A regimen that strongly suppresses pituitary gonadotropins will quiet the ovaries more effectively than one that only partially does so. This is why blanket statements about HRT and cysts tend to miss the mark.
Endometriomas Are a Different Story
Endometriomas, sometimes called “chocolate cysts,” are ovarian cysts formed from endometrial tissue growing where it should not be. Before menopause, endometriosis is driven by estrogen. The hope for many women is that menopause will quiet the disease. It usually does. But HRT reintroduces estrogen, and that can wake up dormant endometriosis.
Case reports have documented postmenopausal women developing new endometriomas after starting HRT, demonstrating that reactivation of endometriosis with hormone therapy is a real, if often overlooked, possibility.3PubMed. Postmenopausal endometrioma and hormonal replacement therapy If you had endometriosis before menopause and are considering HRT, this is a conversation worth having with your doctor. The risk is not theoretical; it has been observed clinically, and it changes the calculus of which HRT regimen is safest for you.
On the treatment side, progestins like dienogest have shown the ability to reduce endometrioma size, and adding estrogen to a dienogest regimen does not appear to undermine that benefit. A retrospective study found that dienogest alone or combined with estrogens was equally effective at shrinking endometriotic cysts over twelve months.4PubMed Central. Dienogest alone or dienogest combined with estrogens in the treatment of ovarian endometriomas, that is the question. A retrospective cohort study This matters because it suggests that if you need HRT and have a history of endometriomas, a combined approach with a progestin component may allow you to manage both menopausal symptoms and endometriotic cysts simultaneously, rather than choosing one over the other.
The Unopposed Estrogen Problem
The type of HRT that raises the most concern for ovarian cysts, and for ovarian health in general, is estrogen given without progesterone. This is often called “unopposed estrogen.” It is typically prescribed to women who have had a hysterectomy, since the primary reason for adding progesterone is to protect the uterine lining. But unopposed estrogen can affect residual ovarian or endometriotic tissue as well.
A systematic review of malignant transformation in postmenopausal endometriosis found that about two-thirds of the women in the reviewed cases had used HRT, and roughly three-quarters of those HRT users were on estrogen-only therapy. Duration mattered too: more than 60% had used HRT for longer than five years. The most common cancers arising from this transformation were endometrioid adenocarcinoma and clear cell carcinoma.5PubMed Central. Malignant Transformation of Postmenopausal Endometriosis: A Systematic Review of the Literature Separate case reports have confirmed that adenocarcinoma can develop within endometriotic tissue in women receiving unopposed estrogen, raising safety concerns about this regimen in anyone with a history of endometriosis.6BJOG: An International Journal of Obstetrics and Gynaecology. Malignant transformation of residual endometriosis in women on unopposed oestrogen hormone replacement therapy
This is a rare but serious outcome. Malignant transformation of endometriosis is uncommon even in HRT users, but the pattern is consistent enough that the literature flags it as a genuine risk, especially with prolonged estrogen-only use. If you have had endometriosis and still have ovarian tissue, the emerging consensus favors combined HRT over unopposed estrogen to mitigate this risk.
HRT and Ovarian Cancer Risk
Ovarian cysts are overwhelmingly benign, but any discussion of HRT and ovarian growths inevitably touches on cancer risk. The evidence here is clearer than many people realize, and not particularly reassuring for long-term users.
A large individual-participant meta-analysis pooling data from 52 epidemiological studies found that women who had ever used HRT had a roughly 20% higher risk of ovarian cancer compared to never-users. Risk was strongly tied to recency: women who were current users at the time of assessment had about a 40% increase in risk. Even women with fewer than five years of use showed a meaningful elevation.7The Lancet. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies A more recent systematic review and meta-analysis confirmed the finding, reporting a similar increase across both cohort and case-control study designs.8PubMed Central. The risk of ovarian cancer in hormone replacement therapy users: a systematic review and meta-analysis
A Swedish population-based study offered additional detail, finding elevated risks of invasive epithelial ovarian cancer in users of both estrogen-only therapy and combined estrogen-progestogen therapy. The greatest risk increases appeared in women who had used hormones for more than ten years, and the elevation was seen across serous, mucinous, and endometrioid subtypes.9PubMed. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women
In absolute terms, ovarian cancer is still relatively rare. A 20 to 40% increase in relative risk translates to a modest increase in absolute risk for any individual woman. But the finding is consistent across multiple large analyses, and it is worth factoring in if you are weighing the benefits and risks of HRT over many years. The risk seems to decline after stopping HRT, but it does not vanish immediately.
Why Estrogen Receptors in Ovarian Tissue Matter
Part of the biological explanation for why HRT can affect ovarian growths lies in estrogen receptor expression. Not all ovarian cysts and tumors respond to estrogen equally. Research examining estrogen receptor alpha (ERα) in ovarian tumors found that the receptor was present in only about 10% of benign serous cysts, but in roughly two-thirds of borderline serous tumors and serous carcinomas. Mucinous tumors showed a different pattern, with very low receptor expression across all grades.10PubMed Central. Paired box gene 2 is associated with estrogen receptor α in ovarian serous tumors: Potential theory basis for targeted therapy
What this means practically is that a simple benign cyst is unlikely to “feed” on HRT’s estrogen in a clinically meaningful way. But a cyst that is already on the spectrum toward borderline or malignant behavior, particularly the serous subtype, is far more likely to have the receptors that respond to estrogen. This is why routine ultrasound follow-up can matter for women on HRT who have known ovarian cysts. A cyst that is stable and clearly benign is not the same concern as one with features that look more complex or borderline.
Do Newer HRT Formulations Reduce the Risk?
The concern about ovarian cysts and HRT has driven interest in newer formulations that might offer symptom relief with fewer ovarian effects. One approach combines conjugated estrogens with bazedoxifene, a selective estrogen receptor modulator, instead of a traditional progestin. A pooled analysis of five large trials found that this combination did not increase ovarian cysts compared to placebo, and neither did any of the other active treatments tested in those trials.11PubMed. Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials The same analysis noted that this combination avoided some of the side effects associated with traditional estrogen-progestogen therapy, including increased breast density and vaginal bleeding.
This does not mean all HRT is equivalent from an ovarian standpoint. The choice of progestin, the dose of estrogen, and whether the regimen is continuous or cyclic all influence ovarian activity differently, as the pituitary-feedback research described earlier makes clear. If ovarian cysts are a specific concern for you, the formulation conversation with your prescriber is not a minor detail. It is central to managing your risk.
Residual Ovary Syndrome and Cyst Formation After Surgery
There is one scenario where ovarian cysts in the context of HRT take on a different character entirely. Women who have had a hysterectomy but retained one or both ovaries can develop what is called residual ovary syndrome. This occurs when the remaining ovarian tissue becomes trapped in scar tissue and adhesions from surgery, and it can lead to chronic pelvic pain and cyst formation.
One particular manifestation of residual ovary syndrome involves pseudocyst formation. These are not true ovarian cysts in the usual sense. They develop when an ovary that is enclosed by adhesions continues to ovulate, but the released fluid has nowhere to go and accumulates in the enclosed space. Women who develop pseudocysts often have a history of multiple pelvic surgeries.12PubMed Central. Pseudocyst Formation in Residual Ovary Syndrome: A Unique Consequence of Ovarian Preservation Whether HRT worsens this process is not well studied, but any hormonal stimulation that promotes residual ovarian activity could theoretically contribute to fluid accumulation in a trapped ovary. If you have had a hysterectomy with ovarian preservation and are experiencing new pelvic pain after starting HRT, a pseudocyst is one possibility worth investigating.
When to Worry and When Not To
The question of whether HRT makes ovarian cysts worse does not have a single clean answer, because ovarian cysts are not a single clean category. For the vast majority of postmenopausal women, standard HRT does not promote the growth of simple functional cysts and may actually reduce their occurrence in the early years after menopause. For women with a history of endometriosis, the calculus changes significantly, especially with estrogen-only therapy used over many years. And for the broader question of ovarian cancer risk, the data consistently show a modest but real elevation tied to HRT use, with the risk climbing the longer therapy continues and dropping after it stops.
A few practical considerations can help you navigate this:
- Know your history: If you had endometriosis before menopause, tell your prescriber, even if you assume it resolved. Residual endometriotic tissue can be reactivated by HRT.
- Avoid unopposed estrogen if you have residual ovarian or endometriotic tissue: Adding a progestin or using a formulation like conjugated estrogens with bazedoxifene may reduce ovarian-related risks.
- Duration matters: The ovarian cancer risk data consistently show greater risk with longer use. Using HRT at the lowest effective dose for the shortest time that meets your needs remains sound guidance.
- Imaging follow-up is reasonable: If you have a known ovarian cyst and are on HRT, periodic ultrasound can help distinguish a stable benign cyst from one that warrants closer attention.
The Overlooked Role of Cyst Subtype in Clinical Decisions
One of the frustrations in clinical practice is that “ovarian cyst” gets treated as though it were a single diagnosis. In reality, the term covers everything from a tiny fluid-filled follicle that will resolve on its own to a complex mass with solid components that needs surgical evaluation. When a woman asks whether HRT will make her ovarian cyst worse, the honest answer depends almost entirely on what kind of cyst she has.
A simple, thin-walled, fluid-filled cyst found incidentally on ultrasound in a postmenopausal woman is almost always benign and is unlikely to be affected by HRT in any meaningful way. A complex cyst with septations, solid areas, or blood flow visible on Doppler may warrant biopsy or closer surveillance regardless of HRT status. And an endometrioma carries its own set of risks with estrogen exposure, as the evidence on reactivation and rare malignant transformation makes clear. Asking “will HRT make my cyst worse?” without specifying the type is a bit like asking “will exercise make my leg worse?” without saying whether you have a bruise or a fracture. The answer depends on what you are starting with, and getting that characterization right is the first step toward a useful conversation about hormone therapy.